Pathogenic mechanism and therapies for Gaucher's disease

Yi chuan = Hereditas
Lin-yu LiuDuan Ma

Abstract

Gaucher's disease (GD) also named glucocerebroside lipidosis, is the most common kind of 1ysosomal storage disorder. It results from an autosomal recessive deficiency of the lysosomal enzyme acid β-glucosidase/ β-glucocerebrosidase (GBA), which is responsible for hydrolysis of glucocerebroside/glucosylceramide (GlcCer) into glucose and ceramide. Absent or reduced enzymatic activity of GBA leads to multisystemic accumulation of GlcCer in mononuclear phagocyte system and various tissues, such as brain, liver, spleen and so on, causing brain injury, liver splenomegaly, bone damage, the reduction of blood cells and individual growth retardation. GD type I could be treated by enzyme replacement therapy (ERT), but GD types II and III have not effective treatment. In this review, we summarize the recent progress on pathogenic mechanism and therapies in GD.

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Brain Injury & Trauma

brain injury after impact to the head is due to both immediate mechanical effects and delayed responses of neural tissues.

Related Papers

South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde
Louisa BhenguSheeba Varughese
Journal of Cytology
Sanjay Sen GuptaMamata Guha Mallick
Zhonghua er ke za zhi. Chinese journal of pediatrics
Yan-long DuanYa-mei Hu
Iranian Journal of Pediatric Hematology and Oncology
F BineshMa Bagherinasab
© 2021 Meta ULC. All rights reserved